taking blood pressure

Journal Club Summary

Khanna A, et al.
N Engl J Med. 2017 Aug 3;377(5):419-430.
Abstract Link

Angiotensin II for the Treatment of Vasodilatory Shock – Promise and Caution.
Dellinger RP, et al.
N Engl J Med. 2017 Aug 3;377(5):486-487.

Methodology Score: 4/5                  
Usefulness Score: 3.5/5

Question and Methods: International multicenter placebo-controlled RCT evaluating the effectiveness of angiotensin II for the treatment of patients with vasodilatory shock refractory to IV fluids and high-dose norepinephrine
Findings: Improvement in MAP seen in 69.9% of patients in angiotensin II group vs 23.4% placebo (OR 7.95)
Limitations: Mortality benefit is unknown, pharmacy-funded study, ICU population
Interpretation: Further studies are needed to establish indications for use (monotherapy vs synergy with other vasopressors), potential side effects to therapy and whether there is a mortality benefit.
By: Dr. Lauren Lacroix

Epi lesson

Surrogate Outcomes
A surrogate outcome is often used in place of a truly clinically important outcome.  This outcome is chosen usually due to feasibility and cost factors.  To obtain a truly clinically important outcome (e.g. survival), it may take a lot longer to obtain an adequate sample size and this often is associated with a much higher costs.  It may be appropriate to use the surrogate if it is truly directly related to the outcome; if not, than it usually is not a suitable outcome and further study is needed.
By: Dr. Jeff Perry  


  • Hans Rosenberg

    Dr. Rosenberg is an emergency physician at the Ottawa Hospital, assistant professor at the University of Ottawa, and Director of the Digital Scholarship and Knowledge Dissemination Program.

    View all posts